A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells

European Journal of Pharmacology

Volumn 669, Issue 1-3, 2011, Pages 38-44

  Shi, Ruizan ^a,b   Li, Wei ^a,c   Zhang, Xiuli ^a   Zhang, Yanjun ^a   Peng, Hongwei ^a   Xie, Yinliang ^a   Fan, Dongmei ^a   Liu, Rong ^a   Liu, Xuyi ^d   Xiong, Dongsheng ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b SHANXI MEDICAL UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

MDR (multidrug resistance); P gp (P glycoprotein); PHII 7; Reversal effect

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; INDIRUBIN; PHII 7; RHODAMINE 123; UNCLASSIFIED DRUG; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INDOLES; P-GLYCOPROTEIN;

EID: 80053297774     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.07.047     Document Type: Article

References (45)

1. S.E. Bates, J.I. Regis, R.W. Robey, Z. Zhan, S. Scala, and B.J. Meadows Chemoresistance in the clinic: overview Bull. Cancer 81 1994 55s 61s
2. G. Batist, A. Tulpule, B.K. Sinha, A.G. Katki, C.E. Myers, and K.H. Cowan Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells J. Biol. Chem 261 1986 15544 15549 (Pubitemid 17208781)
3. C. Carvalho, R.X. Santos, S. Cardoso, S. Correia, P.J. Oliveira, M.S. Santos, and P.I. Moreira Doxorubicin: the good, the bad and the ugly effect Curr. Med. Chem 16 2009 3267 3285
4. F. Chen, L. Li, D. Ma, S. Yan, J. Sun, M. Zhang, C. Ji, and M. Hou Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment Leuk. Res 34 2010 e75 e77
5. S.U. Choi, C.O. Lee, K.H. Kim, E.J. Choi, S.H. Park, H.S. Shin, S.E. Yoo, N.P. Jung, and B.H. Lee Reversal of multidrug resistance by novel verapamil analogs in cancer cells Anticancer. Drugs 9 1998 157 165 (Pubitemid 28080637)
6. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev 58 2006 621 681
7. H.M. Coley Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer Cancer. Treat. Rev 34 2008 378 390
8. K.H. Cowan, G. Batist, A. Tulpule, B. Sinha, and C.E. Myers Similar biochemical changes in human breast cancer cell and carcinogen-induced resistance to xenobiotics Proc. Nati. Acad. Sci. USA 83 1986 9328 9332 (Pubitemid 17223354)
9. M. Dean, Y. Hamon, and G. Chimini The human ATP-binding cassette (ABC) transporter superfamily J. Lipid. Res 42 2001 1007 1017 (Pubitemid 32645780)
10. T. Fojo, and S. Bates Strategies for reversing drug resistance Oncogene 22 2003 7512 7523 (Pubitemid 37487173)
11. W.F. Fong, C.K. Wan, G.Y. Zhu, A. Chattopadhyay, S. Dey, Z. Zhao, and X.L. Shen Schisandrol A from Schisandra chinensis reverses P-glycoprotein- mediated multidrug resistance by affecting Pgp-substrate complexes Planta. Med 73 2007 212 220 (Pubitemid 46917472)
12. M.M. Gottesman, and I. Pastan Biochemistry of multidrug resistance mediated by the multidrug transporter Ann. Rev. Biochem 62 1993 385 427 (Pubitemid 23237876)
13. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58 (Pubitemid 37328807)
14. C.E. Herzog, M. Tsokos, S.E. Bates, and A.T. Fojo Increased MDR-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists J. Biol. Chem 268 1993 2946 2952 (Pubitemid 23057933)
15. S. Hokita, T. Aikou, S. Ishigami, F. Miyazono, A. Nakajo, Y. Uenosono, M. Hamanoue, K. Aridome, and S. Natsugoe Combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer Gan. To. Kagaku. Ryoho 33 2006 95 98
16. P.C. Hsu, H.C. Hun, Y.F. Liao, C.C. Liu, G.J. Tsay, and G.Y. Liu Ornithine decarboxylase attenuates leukemic chemotherapy drugs-induced cell apoptosis and arrest in human promyelocytic HL-60 cells Leuk. Res 32 2008 1530 1540
17. F.H. Igney, and P.H. Krammer Death and anti-death: tumour resistance to apoptosis Nature. Reviews. Cancer 2 2002 277 288 (Pubitemid 37328781)
18. S. Jain, S. Laphookhieo, Z. Shi, L.W. Fu, S. Akiyama, Z.S. Chen, D.T. Youssef, R.W. van Soest, and K.A. El Sayed Reversal of P-glycoprotein mediated multidrug resistance by sipholane triterpenoids J. Nat. Prod 70 2007 928 931 (Pubitemid 47056104)
19. B.S. Ji, and L. He CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in ADRorubicin-resistant human myelogenous leukaemia (K562/ADR) cells J. Pharm. Pharmacol 59 2007 1011 1015 (Pubitemid 47051083)
20. R.W. Johnstone, E. Cretney, and M.J. Smyth P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death Blood 93 1999 1075 1085 (Pubitemid 29067874)
21. L. Kelland The resurgence of platinum-based cancer chemotherapy Nature Reviews. Cancer 7 2007 573 584 (Pubitemid 47106628)
22. R.P. Keller, H.J. Altermatt, K. Nooter, G. Poschmann, J.A. Laissue, P. Bollinger, and P.C. Hiestand SDZ PSC833, a non immunosuppressive cyclosporine: its potency in overcoming P-glycolprotein-mediated multidrug resistance of murine leukemia Int. J. Cancer 50 1992 593 597
23. R.J. Kelly, D. Draper, C.C. Chen, R.W. Robey, W.D. Figg, R.L. Piekarz, X. Chen, E.R. Gardner, F.M. Balis, A.M. Venkatesan, S.M. Steinberg, T. Fojo, and S.E. Bates A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer Clin. Cancer. 17 2011 569 580
24. X. Kong, H. Ge, L. Hou, L. Shi, and Z. Liu Induction of apoptosis in K562/ADM cells by gamma-linolenic acid involves lipid peroxidation and activation of caspase-3 Chem. Biol. Interact 162 2006 140 148 (Pubitemid 44189962)
25. R. Krishna, and L.D. Mayer Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur. J. Pharm Sci 11 2000 265 283
26. I.E. Kuppens, E.O. Witteveen, R.C. Jewell, S.A. Radema, E.M. Paul, S.G. Mangum, J.H. Beijnen, E.E. Voest, and J.H. Schellens A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients Clin. Cancer. Res 13 2007 3276 3285 (Pubitemid 46944913)
27. J.S. Lee, K. Paull, M. Alvarez, C. Hose, A. Monks, M. Grever, A.T. Fojo, and S.E. Bates Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen Mol. Pharmacol 46 1994 627 638 (Pubitemid 24334752)
28. E.M. Leslie, R.G. Deeley, and S.P. Cole Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense Toxicol. Appl. Pharmacol 204 2005 216 237 (Pubitemid 40552845)
29. Y.C. Li, K.P. Fung, T.T. Kwok, C.Y. Lee, Y.K. Suen, and S.K. Kong Mitochondria targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells Chemotherapy 50 2004 55 62 (Pubitemid 38813013)
30. P. Limtrakul, S. Siwanon, S. Yodkeeree, and C. Duangrat Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells Phytomedicine 14 2007 381 389 (Pubitemid 46818013)
31. D.B. Longley, and P.G. Johnston Molecular mechanisms of drug resistance J. Pathol 205 2005 275 292 (Pubitemid 40227997)
32. G.R. Masters, M.A. Berger, and E.F. Albone Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts Gynecologic Oncology 102 2006 462 467 (Pubitemid 44376652)
33. L. Meijer, A.M. Thunnissen, A.W. White, M. Garnier, M. Nikolic, L.H. Tsai, J. Walter, K.E. Cleverley, P.C. Salinas, Y.Z. Wu, and J. Biernat Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent Chem. Biol 7 2000 51 63 (Pubitemid 30141925)
34. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev 56 2004 185 229 (Pubitemid 38720829)
35. F. Morschhauser, P.L. Zinzani, M. Burgess, L. Sloots, F. Bouafia, and C. Dumontet Phase I/II trial of a Pglycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 48 2007 708 715 (Pubitemid 46605542)
36. S. Nobili, I. Landini, B. Giglioni, and E. Mini Pharmacological strategies for overcoming multidrug resistance Curr. Drug. Targets 7 2006 861 879
37. M. Notarbartolo, M. Cervello, L. Dusonchet, and N. D'Alessandro NAIP-deltaEx10-11: a novel splice variant of the apoptosis inhibitor NAIP differently expressed in drug-sensitive and multidrug-resistant HL60 leukemia cells Leuk. Res 26 2002 857 862 (Pubitemid 34778501)
38. T. Ozben Mechanisms and strategies to overcome multiple drug resistance in cancer FEBS. Lett 580 2006 2903 2909 (Pubitemid 43729172)
39. E. Rivera Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes Am. J. Clin. Oncol 33 2010 176 185
40. E. Teodori, S. Dei, C. Martelli, S. Scapecchi, and F. Gualtieri The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR) Current. Drug. Targets 7 2006 893 909
41. H. Thomas, and H.M. Coley Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer. Control 10 2003 159 165 (Pubitemid 36437822)
42. N.K. Verma, G. Singh, and C.S. Dey Miltefosine induces apoptosis in arsenite resistant Leishmania donovani promastigotes through mitochondrial dysfunction Exp. Parasitol 116 2007 1 13 (Pubitemid 46412310)
43. G.H. Wang, H.F. Chen, M.H. Huang, N.L. Wang, J.C. Zhang, Y. Zhang, G. Bai, W.F. Fong, M. Yang, and X. Yao Methyl protodioscin induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells Cancer. Lett 241 2006 102 109
44. Y.J. Zhang, R. Wang, X.F. Shao, D.M. Fan, Y.F. Xu, Y. Zhou, F. Liu, Y. Su, and D.S. Xiong Mechanism of synergistic anti-tumor effect of PH II-7 with doxorubicin on multi-drug resistant HL-60/ADR cells Zhonghua. Xue. Ye. Xue. Za. Zhi 29 2008 599 602
45. B. Zhu, G.T. Liu, Y.M. Zhao, R.S. Wu, and S.J. Strada Chemosensitizing multiple drug resistance of human carcinoma by bicyclol involves attenuate p-glycoprotein, GST-P and Bcl-2 Cancer. Biol. Ther 5 2006 536 543 (Pubitemid 43765290)